Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. - Wikidata - awgldk - TriplyDB

Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy.

Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy.

http://www.wikidata.org/entity/Q37125330

about

Tubulin-interactive natural products as anticancer agents Phytochemicals and Biogenic Metallic Nanoparticles as Anticancer Agents Microtubule-binding agents: a dynamic field of cancer therapeutics.Critical appraisal of cabazitaxel in the management of advanced prostate cancer Update on taxane development: new analogs and new formulations Novel therapies in breast cancer: what is new from ASCO 2008.Management of docetaxel failures in metastatic castrate-resistant prostate cancer.Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer.Microtubule dynamics as a target in oncology.Novel anti-tubulin cytotoxic agents for breast cancer.Larotaxel: broadening the road with new taxanes.Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.Bioengineering approaches to study multidrug resistance in tumor cells.Cabazitaxel: a novel microtubule inhibitor.Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future?Emerging drugs in metastatic breast cancer: an update.Tubulin: an example of targeted chemotherapy.Tubulin inhibitors: a patent review.Early investigational tubulin inhibitors as novel cancer therapeutics.Pharmacokinetics and tissue distribution of larotaxel in rats: comparison of larotaxel solution with larotaxel-loaded folate receptor-targeting amphiphilic copolymer-modified liposomes.New therapeutics to treat castrate-resistant prostate cancer.

P2860

Q24650163-E63AF178-790A-4867-B446-167AFC56D15B Q26750806-483546CE-87FC-483B-B404-5110FB62A43B Q27690249-C45918B2-794D-4DA6-8E3D-B2C749F365DA Q34386577-3F67A080-932F-42BE-8B7D-ED7A3E567C43 Q36470377-D76AC91E-6BBD-4D44-9E74-1BF9D9505B59 Q36964421-C6209CA9-BCF7-42CF-B44C-F472B6E99552 Q37354571-B948C73D-6468-4547-A6C0-CA48D2CA4C1F Q37360151-579FECDD-951F-4C14-A877-91E6B8AE5857 Q37360708-4E01B961-0D2B-46DB-A151-D87BEC0805B2 Q37385373-9A369A67-F5A9-4007-AA23-E9DB645E2BB8 Q37551909-ECAD569E-5F19-4493-873F-CA230E512962 Q37718401-7812C3BD-3E04-4AAD-AFF8-CB9DA201E0CC Q37851027-6ABD7EF5-D98A-4308-B804-77A94122C0C8 Q37902641-C6A4424A-4A16-46EF-8B12-86A39656CA5C Q37928232-39224FD5-5688-4038-8993-DA5D2863929F Q37961957-58B2F83A-18FC-47F9-A26D-18E85C8BC9C1 Q38086872-59D8A1FD-D28D-45A7-8A8E-526B0C9A3CC9 Q38169237-9F6F7C2C-C238-4B64-830A-4277629AAE76 Q38836161-08BF07CA-AFE0-4FFD-8579-3CB2E9A8DABA Q50624181-86F6EF1A-87F7-4C44-AFDD-2C9FA292EA7B Q52641603-38855BD9-A6CA-4A32-A5F7-ED72EEF3448C

P2860

Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy.

http://www.wikidata.org/entity/Q37125330

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Phase II multicenter study of ...... received taxane-based therapy.

@en

Phase II multicenter study of ...... received taxane-based therapy.

@nl

type

label

Phase II multicenter study of ...... received taxane-based therapy.

@en

Phase II multicenter study of ...... received taxane-based therapy.

@nl

prefLabel

Phase II multicenter study of ...... received taxane-based therapy.

@en

Phase II multicenter study of ...... received taxane-based therapy.

@nl

P1433

Q37125330-C5339A85-971E-4DC1-8F5B-A06B31BBC84B

P1476

Q37125330-6E25A9DE-9371-4B20-A8B8-4D3FACFA20C2

P2093

Q37125330-2D18A290-CFC2-4B10-9631-E9365E58AE72

Q37125330-30E47EE2-0A2A-4933-A9B0-B669D47BC90B

Q37125330-3A1420CE-98E2-43FF-8AB3-423C94294061

Q37125330-5640ABD6-8A39-4A98-9C0C-6765ACDE95D4

Q37125330-8796F15B-F4C3-45FC-88D6-DE97A278132A

Q37125330-B51CCAD2-B216-4FAD-9EC4-65C8E4C20059

Q37125330-EEF73306-373C-4145-9360-C9C78856E2DE

Q37125330-FA25F1E4-F17A-4588-B87E-F2DF4B66723E

Q37125330-FD1E0354-1CB1-491E-9C08-502493D24968

P2860

Q37125330-5ADABE61-FF5A-4919-BFE1-ACD4E0535819

Q37125330-5AF86107-B287-4F6F-8909-71B4AF66C8F5

Q37125330-D4978D4A-F202-4646-8A32-6CF10D46E9B0

Q37125330-DC1DE94F-54D6-4A2E-9CF9-DA289B1A4115

Q37125330-F17B7F37-0DF7-4C9B-989E-09A9E81EFEBC

Q37125330-FD19246F-972B-4857-A763-0704A614632C

P304

Q37125330-6BA29162-6B49-4737-A4B5-D2DFF96C31C2

P31

Q37125330-6DEBC4EC-B6E2-42C8-B898-B6D8DDD8B7B5

P356

Q37125330-3B6151B2-4902-4A9F-B6A4-D490F00F522E

P433

Q37125330-EE9CAFB1-D6AD-427C-A3B6-03BFD2E84126

P478

Q37125330-1B2329DD-97AA-490F-8505-7E73BEEA91B3

P577

Q37125330-F936A3B6-1CB2-4475-A74E-07E420FB2E69

P5875

Q37125330-7B5E07B3-8C60-45C0-90B0-17F0FE2EDDDF

P698

Q37125330-61C88C89-7D00-4A2A-82F1-0F0E19DFB7A7

P921

Q37125330-D0016FE4-258F-4F61-8028-002BF143C556

P356

P1433

Annals of Oncology

P1476

Phase II multicenter study of ...... received taxane-based therapy.

@en

P2093

A Lortholary

http://www.w3.org/2001/XMLSchema#string

G Romieu

http://www.w3.org/2001/XMLSchema#string

M Besenval

http://www.w3.org/2001/XMLSchema#string

M Tubiana-Hulin

http://www.w3.org/2001/XMLSchema#string

P Kaufman

http://www.w3.org/2001/XMLSchema#string

S Limentani

http://www.w3.org/2001/XMLSchema#string

V Diéras

http://www.w3.org/2001/XMLSchema#string

V Girre

http://www.w3.org/2001/XMLSchema#string

V Valero

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Confidence intervals for the binomial parameter: some new considerations

Preclinical evaluation of new taxoids.

Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both.

Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.

Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors.

P304

1255-1260

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDN060

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2008-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5472035

http://www.w3.org/2001/XMLSchema#string

P698

18381372

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial